ACP
ADAP

Acuta Capital Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

Acuta Capital Partners’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,165,000
Closed -$11.7M – 44
2020
Q2 		$11.7M Buy
+1,165,000
New +$7.32M 3.37% 9
2015
Q3 		– Sell
-30,000
Closed -$550K – 60
2015
Q2 		$550K Buy
+30,000
New +$515K 0.34% 44

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Acuta Capital Partners's ADAP Position: Q3 2020 in Review

Acuta Capital Partners sold out of Adaptimmune Therapeutics (ADAP) in Q3 2020, closing a stake of 1,165,000 shares — an estimated $11.7M sold.

Acuta Capital Partners first reported a position in ADAP in Q2 2015 and held it in 2 quarters. The position peaked at $11.7M in Q2 2020. 79 funds tracked by Wall St. Rank hold ADAP as of Q3 2020.

  • Acuta Capital Partners reported no remaining Adaptimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 1,165,000 Adaptimmune Therapeutics shares in Q3 2020, an estimated $11.7M.
  • Acuta Capital Partners first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 2 quarters.
  • Acuta Capital Partners's Adaptimmune Therapeutics position peaked at $11.7M in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2020.

Based on Acuta Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.